Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 6/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
| ▸ | TYMP | P19971 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 2/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.45 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.43 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PNP | P00491 | 1/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
| ▸ | KRAS | P01116 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL367384 | 0.82 | POLB (0.65) | HINT1POLBTAAR1TYMPGSK3A | |
| SCHEMBL16609224 | 0.82 | KDM4E (0.56) | HINT1POLBTAAR1TAS1R3TAS1R1 | |
| SCHEMBL24852831 | 0.81 | POLB (0.53) | HINT1POLBTAAR1TAS1R3TAS1R1 | |
| SCHEMBL17279179 | 0.80 | KDM4E (0.54) | HINT1POLBTAAR1TAS1R3TAS1R1 | |
| SCHEMBL7517850 | 0.80 | KDM4E (0.54) | HINT1POLBTAAR1TAS1R3TAS1R1 | |
| SCHEMBL8665070 | 0.80 | KDM4E (0.62) | POLBTAAR1TAS1R3TAS1R1TYMP | |
| SCHEMBL17279165 | 0.80 | KDM4E (0.62) | POLBTAAR1TAS1R3TAS1R1TYMP | |
| SCHEMBL6470562 | 0.80 | KDM4E (0.62) | POLBTAAR1TAS1R3TAS1R1TYMP | |
| SCHEMBL7562193 | 0.80 | POLB (0.51) | HINT1POLBTAS1R3TAS1R1GSK3A | |
| SCHEMBL16609168 | 0.79 | KDM4E (0.52) | POLBTAS1R3TAS1R1TYMPP2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9572891-B2 | Oligonucleotide conjugates | GERON CORPORATION (US) | 2017-02-21 | — | — | US | disclosed |
| US-20150374841-A1 | Oligonucleotide Conjugates | GERON CORPORATION | 2015-12-31 | — | — | US | disclosed |
| US-9072790-B2 | Oligonucleotide conjugates | GERON CORPORATION (US) | 2015-07-07 | — | — | US | disclosed |
| US-20140349292-A1 | OLIGONUCLEOTIDE N3'-->P5' THIOPHOSPHORAMIDATES: THEIR SYNTHESIS AND USE | GERON CORPORATION | 2014-11-27 | — | — | US | disclosed |
| EP-1543021-B1 | OLIGONUCLEOTIDE CONJUGATES | GERON CORP (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20130253042-A1 | Oligonucleotide Conjugates | GERON CORPORATION (US) | 2013-09-26 | — | — | US | disclosed |
| EP-1379689-B1 | OLIGONUCLEOTIDE CONJUGATES | GERON CORP (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20100016416-A1 | Oligonucleotide Conjugates | GERON CORPORATION (US) | 2010-01-21 | — | — | US | disclosed |
| US-7563618-B2 | Oligonucleotide conjugates | GERON CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| EP-1992634-A1 | Oligonucleotide n3'- p5' thiophosphoramidates: their synthesis and use | Geron Corporation (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20070037770-A1 | That retains the high RNA binding affinity of the parent oligonucleotide N3' --> P5' phosphoramidates and exhibits a much higher acid stability; inhibiting human telomerase enzyme activity; solid phase synthesis; kits | GERON CORPORATION | 2007-02-15 | — | — | US | disclosed |
| US-7138383-B2 | That retains the high RNA binding affinity of the parent oligonucleotide N3' --> P5' phosphoramidates and exhibits a much higher acid stability; inhibiting human telomerase enzyme activity | GERON CORPORATION (US) | 2006-11-21 | — | — | US | disclosed |
| US-20050049408-A1 | That retains the high RNA binding affinity of the parent oligonucleotide N3' --> P5' phosphoramidates and exhibits a much higher acid stability; inhibiting human telomerase enzyme activity; solid phase synthesis; kits | GERON CORPORATION | 2005-03-03 | — | — | US | disclosed |
| US-6835826-B2 | Acid resistance, stability; telomerase inhibitor | GERON CORPORATION | 2004-12-28 | — | — | US | disclosed |
| US-20030212032-A1 | Acid resistance, stability; telomerase inhibitor | GERON CORPORATION | 2003-11-13 | — | — | US | disclosed |
| US-6608036-B1 | Inhibit telomerase enzyme activity; inhibit proliferation of cell that expresses telomerase | GERON CORPORATION | 2003-08-19 | — | — | US | disclosed |
| US-20030138814-A1 | Comprises RNA and nucleobase/fluorophore for inhibition of human telomerase activity (inhibits growth of cancerous cells) | GERON CORPORATION | 2003-07-24 | — | — | US | disclosed |
| EP-0882059-B1 | SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDE N3-'P5'- PHOSPHORAMIDATES | LYNX THERAPEUTICS INC (US) | 2002-02-06 | — | — | EP | disclosed |
| EP-0882059-A1 | SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDE N3-'P5'- PHOSPHORAMIDATES | LYNX THERAPEUTICS, INC. (US) | 1998-12-09 | — | — | EP | disclosed |
| WO-1997031009-A1 | SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDE N3'→P5' PHOSPHORAMIDATES | LYNX THERAPEUTICS, INC. (US) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374841-A1 | Oligonucleotide Conjugates | TERT, RNGTT, TRDMT1 | HINT1 1632/4885POLB 79/4885TAAR1 2259/4885 |
| US-20130253042-A1 | Oligonucleotide Conjugates | TERT, RNGTT, TRDMT1 | HINT1 1632/4885POLB 79/4885TAAR1 2259/4885 |
| US-20050049408-A1 | That retains the high RNA binding affinity of the parent oligonucleotide N3' --> P5' phosphoramidates and exhibits a much higher acid stability; inhibiting human telomerase enzyme activity; solid phase synthesis; kits | RNGTT, MTAP, TYMP | HINT1 186/4885POLB 202/4885TAAR1 4331/4885 |
| US-20030138814-A1 | Comprises RNA and nucleobase/fluorophore for inhibition of human telomerase activity (inhibits growth of cancerous cells) | TERT, RNGTT, DUT | HINT1 1254/4885POLB 151/4885TAAR1 1976/4885 |
| US-20030212032-A1 | Acid resistance, stability; telomerase inhibitor | NT5C3B, MTAP, TERT | HINT1 167/4885POLB 304/4885TAAR1 3950/4885 |
| US-20070037770-A1 | That retains the high RNA binding affinity of the parent oligonucleotide N3' --> P5' phosphoramidates and exhibits a much higher acid stability; inhibiting human telomerase enzyme activity; solid phase synthesis; kits | RNGTT, MTAP, TYMP | HINT1 186/4885POLB 202/4885TAAR1 4331/4885 |
| US-20140349292-A1 | OLIGONUCLEOTIDE N3'-->P5' THIOPHOSPHORAMIDATES: THEIR SYNTHESIS AND USE | MTAP, NT5C3B, RNGTT | HINT1 99/4885POLB 398/4885TAAR1 4439/4885 |
| US-20100016416-A1 | Oligonucleotide Conjugates | TERT, RNGTT, TRDMT1 | HINT1 1632/4885POLB 79/4885TAAR1 2259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.